Want to see TSE:NEVI full AI Analyst Report?
Pascal Biosciences Inc (NEVI) Ratios
Pascal Biosciences Inc Ratios
TSE:NEVI's free cash flow for Q2 2026 was $19.79K. For the 2026 fiscal year, TSE:NEVI's free cash flow was increased by $0.00 and operating cash flow was $19.79K. See a summary of the company’s cash flow.
| Ratios | Nov 25 | Feb 25 | Feb 24 | Nov 22 | Feb 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.75 | 1.08 | 0.79 | 0.02 | 0.22 |
| Quick Ratio | 0.45 | 0.51 | 0.57 | 0.02 | 0.22 |
| Cash Ratio | 0.14 | 0.23 | 0.37 | 0.01 | 0.00 |
| Solvency Ratio | -0.02 | -0.14 | -0.26 | -0.49 | -1.66 |
| Operating Cash Flow Ratio | 0.08 | -0.21 | -0.34 | -0.17 | -0.95 |
| Short-Term Operating Cash Flow Coverage | 0.25 | -0.42 | -0.56 | -0.66 | -79.25 |
| Net Current Asset Value | $ -189.00K | $ -192.75K | $ -237.43K | $ -944.11K | $ -501.28K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.14 | 0.26 | 0.27 | 11.93 | 0.05 |
| Debt-to-Equity Ratio | 0.25 | 0.43 | 0.50 | -0.24 | -0.02 |
| Debt-to-Capital Ratio | 0.20 | 0.30 | 0.33 | -0.31 | -0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.16 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.77 | 1.66 | 1.81 | -0.02 | -0.32 |
| Debt Service Coverage Ratio | -0.11 | -0.14 | -0.40 | -2.05 | -79.96 |
| Interest Coverage Ratio | -5.38 | -3.50 | 0.00 | -142.75 | -193.56 |
| Debt to Market Cap | 0.12 | 0.13 | 0.36 | 0.17 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.02 | 0.03 | 0.02 | 0.00 |
| Net Debt to EBITDA | -4.35 | -8.29 | -0.97 | -0.46 | -0.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 23.37% | 69.45% | 58.51% | 0.00% | 0.00% |
| EBIT Margin | -17.13% | -19.32% | -56.36% | 0.00% | 0.00% |
| EBITDA Margin | -1.93% | -3.10% | -40.44% | 0.00% | 0.00% |
| Operating Profit Margin | -17.13% | -14.20% | -129.27% | 0.00% | 0.00% |
| Pretax Profit Margin | -16.22% | -23.39% | -59.53% | 0.00% | 0.00% |
| Net Profit Margin | -16.22% | -23.39% | -59.53% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -16.22% | -23.39% | -59.53% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 94.71% | 164.65% | 46.05% | 86.24% | 100.73% |
| Return on Assets (ROA) | -16.04% | -17.78% | -16.02% | -2551.56% | -701.69% |
| Return on Equity (ROE) | -28.39% | -29.58% | -29.05% | 50.87% | 221.65% |
| Return on Capital Employed (ROCE) | -29.98% | -15.01% | -63.07% | 66.90% | 220.04% |
| Return on Invested Capital (ROIC) | -23.94% | -12.55% | -42.15% | 91.63% | 223.57% |
| Return on Tangible Assets | -48.23% | -56.36% | -44.35% | -2551.56% | -701.69% |
| Earnings Yield | -13.87% | -9.01% | -21.24% | -36.64% | -20.18% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.53 | 9.97 | 3.25 | 0.00 | 0.00 |
| Payables Turnover | 4.89 | 1.66 | 0.86 | 0.00 | 0.00 |
| Inventory Turnover | 5.81 | 1.43 | 1.12 | 0.00 | 0.00 |
| Fixed Asset Turnover | 130.88 | 69.27 | 33.88 | 0.00 | 0.00 |
| Asset Turnover | 0.99 | 0.76 | 0.27 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | -24.08 | -16.38 | -1.26 | 0.00 | 0.00 |
| Cash Conversion Cycle | 36.68 | 72.19 | 14.56 | 0.00 | 0.00 |
| Days of Sales Outstanding | 48.47 | 36.62 | 112.42 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 62.87 | 255.39 | 325.26 | 0.00 | 0.00 |
| Days of Payables Outstanding | 74.66 | 219.82 | 423.12 | 0.00 | 0.00 |
| Operating Cycle | 111.34 | 292.01 | 437.68 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.00 | -0.00 | -0.02 | -0.01 | -0.05 |
| Free Cash Flow Per Share | 0.00 | -0.00 | -0.02 | -0.01 | -0.05 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -10.42 | -74.93 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -10.42 | -74.93 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.25 | -0.23 | -0.56 | -0.66 | -79.25 |
| Operating Cash Flow to Sales Ratio | 0.04 | -0.08 | -0.57 | 0.00 | 0.00 |
| Free Cash Flow Yield | 3.13% | -3.28% | -20.75% | -11.27% | -11.40% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.25 | -11.10 | -4.71 | -2.73 | -4.96 |
| Price-to-Sales (P/S) Ratio | 1.17 | 2.60 | 2.80 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.05 | 3.28 | 1.37 | -1.39 | -10.98 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 31.93 | -30.47 | -4.82 | -8.88 | -8.78 |
| Price-to-Operating Cash Flow Ratio | 31.93 | -33.40 | -4.88 | -8.88 | -8.78 |
| Price-to-Earnings Growth (PEG) Ratio | 0.26 | 0.25 | 0.09 | 0.05 | 0.23 |
| Enterprise Value Multiple | -65.06 | -92.01 | -7.91 | -3.26 | -5.06 |
| Enterprise Value | 2.13M | 4.42M | 2.15M | 1.53M | 5.40M |
| EV to EBITDA | -65.06 | -92.01 | -7.91 | -3.26 | -5.06 |
| EV to Sales | 1.25 | 2.85 | 3.20 | 0.00 | 0.00 |
| EV to Free Cash Flow | 34.22 | -33.49 | -5.50 | -10.34 | -8.79 |
| EV to Operating Cash Flow | 34.22 | -36.71 | -5.57 | -10.34 | -8.79 |
| Tangible Book Value Per Share | -0.00 | -0.00 | -0.01 | -0.07 | -0.04 |
| Shareholders’ Equity Per Share | 0.02 | 0.03 | 0.06 | -0.07 | -0.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.04 | 0.04 | 0.03 | 0.00 | 0.00 |
| Net Income Per Share | -0.01 | -0.01 | -0.02 | -0.04 | -0.09 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.95 | 1.21 | 1.06 | 1.01 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 |
| SG&A to Revenue | 0.41 | 0.63 | 1.41 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.02 | 0.61 | 0.00 | 0.00 |
| Income Quality | -0.23 | 0.33 | 0.96 | 0.31 | 0.56 |
Currency in CAD
